In the medical research landscape, exciting breakthroughs often emerge from unexpected sources. Recent studies conducted by researchers at the Salk Institute have discovered cannabinol (CBN) as a promising candidate for addressing neurodegenerative diseases such as Alzheimer’s and Parkinson’s. These findings, published in the journal Redox Biology, underscore a new frontier in the search to combat debilitating neurological disorders.
We recognise the urgent need for effective treatments that address the underlying mechanisms of neurodegeneration, rather than merely providing symptomatic relief. With the aging population facing an increasing prevalence of these conditions, the demand for innovative therapeutic solutions has never been more pressing.
CBN, a naturally occurring compound derived from the cannabis plant, has emerged as a potential candidate in this landscape. Unlike its psychoactive counterpart THC, CBN demonstrates neuroprotective effects without inducing undesirable psychoactive effects. Previous research has highlighted CBN’s ability to preserve mitochondrial function in brain cells, a crucial factor in cell survival and energy production—a process often compromised in neurodegenerative diseases.
Building upon these initial discoveries, the researchers initiated a rigorous exploration of CBN and its derivatives, aiming to optimise its therapeutic potential. Through meticulous fragment-based drug discovery techniques, key components of the CBN molecule responsible for its neuroprotective effects were discovered – not only does CBN protect brain cells from age-related damage, but its chemically modified versions could be even more effective.
These findings represent a significant step forward in the global mission to develop novel therapeutics for neurodegenerative diseases. While the journey from preclinical research to clinical translation is complex and multifaceted, the industry’s commitment to advancing these promising compounds remains unwavering.
“Not only does CBN have neuroprotective properties, but its derivatives have the potential to become novel therapeutics for various neurological disorders,” said Research Professor Pamela Maher, the senior author of the study. “We were able to pinpoint the active groups in CBN that are doing that neuroprotection, then improve them to create derivative compounds that have greater neuroprotective ability and drug-like efficacy.”
Zhibin Liang, the study’s first author and postdoctoral researcher in Maher’s lab explained, “We were looking for CBN analogs that could get into the brain more efficiently, act more quickly, and produce a stronger neuroprotective effect than CBN itself. The four CBN analogs we landed on had improved medicinal chemical properties, which was exciting and really important to our goal of using them as therapeutics.”
Among the four CBN derivatives, one analogue, referred to as CP1, demonstrated particularly strong protective effects. In the cell culture tests, CP1 and its counterparts successfully reduced the incidence of cell death triggered by neurotoxic conditions.
As the therapeutic potential of CBN and its derivatives continue to be explored, we remain dedicated to demanding scientific inquiry, ethical research practices, and patient-centric innovation; promoting a new era of hope and healing for individuals affected by neurodegenerative diseases worldwide.
Back to News + Insights